<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01954953</url>
  </required_header>
  <id_info>
    <org_study_id>P13-02</org_study_id>
    <nct_id>NCT01954953</nct_id>
  </id_info>
  <brief_title>Clinical and Genetic Examination of Usher Syndrome Patients' Cohort in Europe</brief_title>
  <acronym>EURUSH</acronym>
  <official_title>European Research Projects on Rare Diseases Driven by Young Investigators</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to characterize Usher patients in order to correlate this data with genetic
      information.

      Tasks:

        -  Standardization and improvement of Usher syndrome diagnosis: refine and elaborate
           special tests of visual and otological function in association with genotype that enable
           to determine the most significant markers for Usher disease progression and therapeutic
           effect.

        -  Perform genotype and phenotype correlations in Usher syndrome patients

        -  Develop and maintain database for phenotypically and genotypically well-characterized
           patient cohorts, suitable for future therapeutic trials
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Genotype and phenotype correlations in Usher syndrome patients</measure>
    <time_frame>up to 3 years (2016)</time_frame>
    <description>Protocol outline: patients undergo clinical and molecular studies. These include extensive ophthalmologic (best corrected visual acuity, refraction, tonometry, color vision, visual field testing, pupillography*, full-field electroretinogram, multifocal electroretinogram, autofluorescence imaging, optical coherence tomography, adaptive optics*) examination, audiologic and vestibular evaluation and obtaining blood samples for genetic analysis.
*only if available</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Usher Syndrome</condition>
  <arm_group>
    <arm_group_label>no intervention</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        USH1, USH2 and USH3 as defined by the Usher syndrome consortium
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Clinical characteristics for USH1, USH2 and USH3 as defined by the Usher syndrome
             consortium;

          -  Informed consent and agreement to participate in the study;

          -  Distance best corrected visual acuity ≥ 0.1.

        Exclusion criteria:

          -  Systemic pathologies or severe ocular pathologies, systemic or topical medication
             usage, and/or other otolaryngology pathologies which could contaminate the results;

          -  Unwillingness to provide a blood sample ;

          -  Unwilling and/or unable to undergo the study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ieva Sliesoraityte, MD PhD</last_name>
    <email>ieva.sliesoraityte@inserm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU, Laboratoire de génétique moléculaire, INSERM</name>
      <address>
        <city>Montpellier</city>
        <zip>34093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christel Vaché, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Christel Vaché, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CIC of CHNO des Quinze-vingts</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Vinet</last_name>
      <phone>+33140021126</phone>
      <email>lvinet@quinze-vingts.fr</email>
    </contact>
    <investigator>
      <last_name>Jose-Alain Sahel, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ieva Sliesoraityte, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg University of Mainz, Institute of Zoology, Dept. Cell and Matrix Biology Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerstin Nagel-Wolfrum, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Kerstin Nagel-Wolfrum, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre, Dept. Otorhinolaryngology</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erwin van Wijk, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Erwin van Wijk, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AIBILI, 4C - Coimbra Coordinating Centre for Clinical Research</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-548</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leal Sérgio Casimiro da Silva</last_name>
    </contact>
    <investigator>
      <last_name>Leal Sérgio Casimiro da Silva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IBILI- Faculty of Medicine - University of Coimbra, Center for Hereditary Diseases and Visual Neurosciences Laboratory</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-548</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo José Gil Duarte Silva, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Eduardo José Gil Duarte Silva, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Portugal</country>
  </location_countries>
  <link>
    <url>http://www.institut-vision.org/index.php?lang=en</url>
    <description>Institut de la Vision</description>
  </link>
  <reference>
    <citation>Sliesoraityte I, Troeger E, Bernd A, Kurtenbach A, Zrenner E. Correlation between spectral domain OCT retinal nerve fibre layer thickness and multifocal pattern electroretinogram in advanced retinitis pigmentosa. Adv Exp Med Biol. 2012;723:471-8. doi: 10.1007/978-1-4614-0631-0_59.</citation>
    <PMID>22183366</PMID>
  </reference>
  <reference>
    <citation>Overlack N, Goldmann T, Wolfrum U, Nagel-Wolfrum K. Gene repair of an Usher syndrome causing mutation by zinc-finger nuclease mediated homologous recombination. Invest Ophthalmol Vis Sci. 2012 Jun 26;53(7):4140-6. doi: 10.1167/iovs.12-9812.</citation>
    <PMID>22661463</PMID>
  </reference>
  <reference>
    <citation>Goldmann T, Rebibo-Sabbah A, Overlack N, Nudelman I, Belakhov V, Baasov T, Ben-Yosef T, Wolfrum U, Nagel-Wolfrum K. Beneficial read-through of a USH1C nonsense mutation by designed aminoglycoside NB30 in the retina. Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6671-80. doi: 10.1167/iovs.10-5741. Epub 2010 Jul 29.</citation>
    <PMID>20671281</PMID>
  </reference>
  <reference>
    <citation>Kersten FF, van Wijk E, Hetterschijt L, Bauβ K, Peters TA, Aslanyan MG, van der Zwaag B, Wolfrum U, Keunen JE, Roepman R, Kremer H. The mitotic spindle protein SPAG5/Astrin connects to the Usher protein network postmitotically. Cilia. 2012 Apr 25;1(1):2. doi: 10.1186/2046-2530-1-2.</citation>
    <PMID>23351521</PMID>
  </reference>
  <reference>
    <citation>Overlack N, Kilic D, Bauss K, Märker T, Kremer H, van Wijk E, Wolfrum U. Direct interaction of the Usher syndrome 1G protein SANS and myomegalin in the retina. Biochim Biophys Acta. 2011 Oct;1813(10):1883-92. doi: 10.1016/j.bbamcr.2011.05.015. Epub 2011 Jul 13.</citation>
    <PMID>21767579</PMID>
  </reference>
  <reference>
    <citation>Estrada-Cuzcano A, Koenekoop RK, Senechal A, De Baere EB, de Ravel T, Banfi S, Kohl S, Ayuso C, Sharon D, Hoyng CB, Hamel CP, Leroy BP, Ziviello C, Lopez I, Bazinet A, Wissinger B, Sliesoraityte I, Avila-Fernandez A, Littink KW, Vingolo EM, Signorini S, Banin E, Mizrahi-Meissonnier L, Zrenner E, Kellner U, Collin RW, den Hollander AI, Cremers FP, Klevering BJ. BBS1 mutations in a wide spectrum of phenotypes ranging from nonsyndromic retinitis pigmentosa to Bardet-Biedl syndrome. Arch Ophthalmol. 2012 Nov;130(11):1425-32. doi: 10.1001/archophthalmol.2012.2434.</citation>
    <PMID>23143442</PMID>
  </reference>
  <reference>
    <citation>García-García G, Besnard T, Baux D, Vaché C, Aller E, Malcolm S, Claustres M, Millan JM, Roux AF. The contribution of GPR98 and DFNB31 genes to a Spanish Usher syndrome type 2 cohort. Mol Vis. 2013;19:367-73. Epub 2013 Feb 13.</citation>
    <PMID>23441107</PMID>
  </reference>
  <reference>
    <citation>Vaché C, Besnard T, le Berre P, García-García G, Baux D, Larrieu L, Abadie C, Blanchet C, Bolz HJ, Millan J, Hamel C, Malcolm S, Claustres M, Roux AF. Usher syndrome type 2 caused by activation of an USH2A pseudoexon: implications for diagnosis and therapy. Hum Mutat. 2012 Jan;33(1):104-8. doi: 10.1002/humu.21634. Epub 2011 Nov 16.</citation>
    <PMID>22009552</PMID>
  </reference>
  <reference>
    <citation>Stoetzel C, Laurier V, Davis EE, Muller J, Rix S, Badano JL, Leitch CC, Salem N, Chouery E, Corbani S, Jalk N, Vicaire S, Sarda P, Hamel C, Lacombe D, Holder M, Odent S, Holder S, Brooks AS, Elcioglu NH, Silva ED, Rossillion B, Sigaudy S, de Ravel TJ, Lewis RA, Leheup B, Verloes A, Amati-Bonneau P, Mégarbané A, Poch O, Bonneau D, Beales PL, Mandel JL, Katsanis N, Dollfus H. BBS10 encodes a vertebrate-specific chaperonin-like protein and is a major BBS locus. Nat Genet. 2006 May;38(5):521-4. Epub 2006 Apr 2. Erratum in: Nat Genet. 2006 Jun;38(6):727. Da Silva, Eduardo [corrected to Silva, Eduardo D].</citation>
    <PMID>16582908</PMID>
  </reference>
  <reference>
    <citation>Castelo-Branco M, Mendes M, Sebastião AR, Reis A, Soares M, Saraiva J, Bernardes R, Flores R, Pérez-Jurado L, Silva E. Visual phenotype in Williams-Beuren syndrome challenges magnocellular theories explaining human neurodevelopmental visual cortical disorders. J Clin Invest. 2007 Dec;117(12):3720-9.</citation>
    <PMID>18037993</PMID>
  </reference>
  <reference>
    <citation>Goldmann T, Overlack N, Wolfrum U, Nagel-Wolfrum K. PTC124-mediated translational readthrough of a nonsense mutation causing Usher syndrome type 1C. Hum Gene Ther. 2011 May;22(5):537-47. doi: 10.1089/hum.2010.067. Epub 2011 Mar 25.</citation>
    <PMID>21235327</PMID>
  </reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2013</study_first_submitted>
  <study_first_submitted_qc>September 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2013</study_first_posted>
  <last_update_submitted>February 3, 2015</last_update_submitted>
  <last_update_submitted_qc>February 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Retinitis Pigmentosa Syndromic</keyword>
  <keyword>Congenital Deafness</keyword>
  <keyword>Usher Syndrome Retinitis Pigmentosa and Deafness</keyword>
  <keyword>Progressive Hearing Loss</keyword>
  <keyword>Retinitis Pigmentosa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Usher Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

